Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mongersen (GED-0301) in Active Crohn's Disease
NCT02367183Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Apr 2015
- Primary completion
- Sep 2016
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial of mongersen in Crohn's disease (3 arms), sponsored by Celgene Corporation. Primary endpoint: Change in Simple Endoscopic Score for Crohn's Disease at 12 weeks. Started Apr 2015; status: completed.
02
Drugs
mongersen
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02367183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02367183.